Cognition Therapeutics to Showcase Alzheimer's Research at Needham Virtual Healthcare Conference
Cognition Therapeutics to Present at Needham Virtual Healthcare Conference
Benzinga
Image: Benzinga
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company based in Purchase, New York, will present at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026. CEO Lisa Ricciardi will discuss the company's advancements in treatments for Alzheimer's disease and dementia with Lewy bodies.
- 01Cognition Therapeutics will present at the Needham Virtual Healthcare Conference on April 13, 2026.
- 02CEO Lisa Ricciardi will provide updates on Alzheimer's disease and dementia with Lewy bodies.
- 03The company is developing zervimesine (CT1812), an investigational therapy showing promise in clinical trials.
- 04Cognition Therapeutics has received nearly $200 million in grants to support its research.
- 05Zervimesine is set to advance into late-stage clinical trials for DLB psychosis.
Advertisement
In-Article Ad
Cognition Therapeutics, Inc. (NASDAQ:CGTX), headquartered in Purchase, New York, will present at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, at 3:00 p.m. Eastern Time. CEO Lisa Ricciardi will discuss the company's progress in developing treatments for Alzheimer's disease and dementia with Lewy bodies (DLB). The company is focused on its lead candidate, zervimesine (CT1812), which has shown promise in Phase 2 clinical trials for DLB and mild-to-moderate Alzheimer's disease. Cognition Therapeutics has received nearly $200 million in funding from the National Institutes of Health and other foundations to support its research efforts. The company plans to advance zervimesine into late-stage clinical trials targeting DLB psychosis, reflecting the significant unmet needs in this area. A live webcast of the presentation will be available on the company's Investor Relations website, and an archived replay will be accessible for 90 days following the event.
Advertisement
In-Article Ad
The advancements in treatment for Alzheimer's and DLB could significantly benefit patients and families affected by these neurodegenerative disorders, potentially reducing caregiver burden and improving quality of life.
Advertisement
In-Article Ad
Reader Poll
How important do you think advancements in Alzheimer's treatments are?
Connecting to poll...
Read the original article
Visit the source for the complete story.